Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 11,595 Shares of Stock

Key Points

• Hims & Hers Health CFO Oluyemi Okupe sold 11,595 shares at an average price of $57.72, totaling over $669,000, resulting in a 14.17% decrease in his ownership.
• Following the insider selling, Hims & Hers Health's stock price rose by 5.6%, reaching $57.83, with a market cap of $13.07 billion.
• Analysts have set varying price targets for Hims & Hers Health, with ratings ranging from "buy" to "hold," reflecting mixed sentiments about the company's future performance.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,595 shares of the company's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $57.72, for a total transaction of $669,263.40. Following the completion of the transaction, the chief financial officer owned 70,232 shares in the company, valued at $4,053,791.04. This represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.20, for a total value of $5,117,000.00.
• On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16.
• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.69, for a total transaction of $505,973.89.
• On Monday, July 14th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.70, for a total transaction of $552,413.70.

Hims & Hers Health Stock Up 5.6%

Shares of NYSE HIMS traded up $3.07 during trading hours on Tuesday, hitting $57.83. 32,917,299 shares of the stock were exchanged, compared to its average volume of 32,735,902. The company has a market cap of $13.07 billion, a PE ratio of 72.29, a PEG ratio of 3.55 and a beta of 2.25. Hims & Hers Health, Inc. has a 12 month low of $17.36 and a 12 month high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a fifty day moving average price of $51.39 and a 200-day moving average price of $47.49.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on HIMS shares. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Canaccord Genuity Group reissued a "buy" rating and issued a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a report on Saturday, September 27th. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of "Reduce" and an average target price of $38.92.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $213,000. UMB Bank n.a. boosted its holdings in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the last quarter. Baldwin Wealth Partners LLC MA increased its holdings in shares of Hims & Hers Health by 128.8% during the 1st quarter. Baldwin Wealth Partners LLC MA now owns 21,871 shares of the company's stock worth $646,000 after buying an additional 12,314 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Hims & Hers Health by 12.9% during the 1st quarter. Farther Finance Advisors LLC now owns 8,122 shares of the company's stock valued at $252,000 after buying an additional 930 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Hims & Hers Health by 128.5% in the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock valued at $152,000 after acquiring an additional 2,892 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.